November 25, 2024 7:54am
Short trading week, U.S. markets are closed Thursday due to the Thanksgiving holiday and close early on Friday, so trading volume is likely to be light this week
Also hoping to suffer from a compound called tryptophan; an amino acid creating serotonin in the body from eating turkey to play a role in my sleep regulation
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
MY Pre-Open Thoughts: “let ‘em run”
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
News: Intellia Therapeutics (NTLA +$0.35) the U.S. FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo CRISPR-based investigational therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
News: Alnylam Pharmaceuticals (ALNY +$6.22), the FDA has accepted for review the supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Based on the use of a Priority Review Voucher, the FDA has set an action date goal of March 23, 2025, under the Prescription Drug User Fee Act (PDUFA). The FDA has informed that it is not planning to hold an advisory committee meeting at this time to review the application.
Friday’s night’s … RegMed Investors (RMi) Closing Bell: Ascension for the sector needy … https://www.regmedinvestors.com/articles/13710
Monday: The pre-open Dow futures are UP +0.67% (+259 points), the S&P futures are UP +0.49% or (+29 points) and the Nasdaq futures are UP +0.47% or (+111 points)
- U.S. stock futures climbed Monday, 11/25,
- European stocks were slightly lower,
- Asia-Pacific markets mostly rose.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
the Dow closed at a new record on Friday, capping off gained 426.16 points, or +0.97%, to 44,296.51, a new all-time closing high and its 3rd straight positive session. The S&P 500 added 20.53 points or +0.35% for its 5th winning session in a row while the Nasdaq rose 31.23 points or +0.16%.
- After a winning week; the Dow ended +2% higher, while the S&P 500 and Nasdaq each added about 1.7%.
- The small cap-focused Russell 2000 outperformed. The index climbed 1.8% on Friday, raising its weekly advance to nearly 4.5%
Economic Data Docket: None Monday, Thursday and Friday
Q4/24: November 9 negative and 7 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Better part of valor to not lead any investor to temptation.
- These are the best of times and the worst of times.
- Sector equity year-to-date performance remains bottom-based. Expect volatility to be more the norm versus exception.
- Watch the “numbers, charts and indicators” measure the daily, weekly, and monthly charts to filter out or lessen the noise of back-and-forth share pricing from the sector rotation.
- My riff on the week, “let ‘em roll”
The BOTTOM LINE: While a holiday-shortened trading week will limit stock action …
- I tend to watch aftermarket responses and all I see/read are positive trends.
However, they (aftermarket responses) will only … last so long … also, forget Robert Kennedy, Jr, and recent news flashes; if he interrupts real scientific drug development and any recurring market lapses – he will be gone!
- He is a short-termer to put government people, health programs and regulatory policies in their place, hopefully for the better!!
Different topic for the week; expect more signs of that stalling in the coming Wednesday's Personal Consumption Expenditures (PCE) release.
- Economists expect annual "core" PCE — which excludes the volatile categories of food and energy — to have clocked in at 2.8% in October, up from the 2.7% seen in September.
- Over the prior month, economists project "core" PCE at 0.3%, unchanged from September.
Ranking the end of November's last week: the previous week ...
- 11/22 – Friday: closed positive with 25 incliner, 9 decliners and 1 flat
- 11/21 - Thursday: closed positive with 18 incliner, 16 decliners and 1 flat
- 11/20 – Wednesday: closed negative with 15 incliner, 17 decliners and 3 flats
- 11/19 - Tuesday closed positive with 19 incliner, 14 decliners and 2 flats
- 11/18 – Monday closed negative with 14 incliner, 20 decliners and 1 fla
I haven’t changed my tune; it’s time for the oversold to continue to be recognized, one of my calling cards with words!
- A further injection of sentiment mixed with conviction needed.
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
